Skip to main content
EnglishEN
European Commission logo print header

Next generation toolbox for greener pharmaceuticals design & manufacturing towards reduced environmental impact

Project description

DEENESFRITPL

Turning medicines green to reduce pollution

The medicines that save us could end up harming us if not disposed of properly. Unfortunately, the concentration of pharmaceuticals in waterways is reaching dangerous levels. In this context, the EU-funded ENVIROMED project will narrow the knowledge gap when it comes to the effect of pharmaceutical compounds, and their derivatives, on the environment. ENVIROMED will shed light on the environmental impact of such compounds, throughout their lifecycle. The findings will provide information about the occurrence of pharmaceuticals in the environment, their persistence and environmental fate. The project will also aim to develop a set of technologies that enable greener and overall, more efficient pharmaceutical production.

Objective

Pharmaceuticals have undoubtably made our world a better place, ensuring longer and healthier lives. However, pharmaceuticals and their active metabolites are rapidly emerging environmental toxicants. It is thus critical that we fully understand, and mitigate where nec-essary, the environmental impact resulting from their production, use and disposal. In this direction, ENVIROMED addresses two aspects of the environmental impact of pharmaceuticals, a) impact of the processes in manufacturing the compound, and b) impact of the compound itself, during its lifecycle. The project narrows the knowledge gap when it comes to the effect of pharmaceutical compounds, and their derivatives, in the environment as it enables the better understanding the environmental impact of such compounds, throughout their lifecycle. It aims to offer (via extensive monitoring campaigns & scientific studies) information regarding occurrence of pharmaceuticals in the environment, their persistence, environmental fate, and toxicity (via in-vitro & in-vivo models) as well as application of in-silico methods to provide information about the basic risk management and fate prediction in the environment. Brief ideas about toxicity endpoints, available ecotoxicity databases, and expert systems employed for rapid toxicity predictions of ecotoxicity of pharmaceuticals will also be taken into account, in order to have a comprehensive approach to pharmaceuticals' Lifecycle Assessment (LCA). Moreover, the project aims at developing a set of technologies that enable greener and overall, more efficient pharmaceuticals production, which include: a) Green-by-design in-silico drug development; b) Novel sensing to allow reduction of rinsing chemicals and cycles; c) a robust Continuous Biomanufacturing line (CBM), which makes use of AI-enabled process optimisation and prediction, using data assimilation based on chemical sensing and energy disaggregation/monitoring. Training activities and a robust exploitation

Fields of science

Keywords

Programme(s)

Topic(s)

Call for proposal

HORIZON-HLTH-2021-IND-07

See other projects for this call

Funding Scheme

RIA - Research and Innovation action

Coordinator

RISA SICHERHEITSANALYSEN GMBH
Net EU contribution
€ 902 500,00
Address
Xantener strasse 11
10707 Berlin
Germany

See on map
Region
Berlin Berlin Berlin
Links
Other funding
€ 0,00

Participants (14)

Partners (2)

Share this page

Download

EC signature date 22 May 2022
Last update: 2 August 2022

My Booklet

Permalink: https://cordis.europa.eu/project/id/101057844

European Union, 2023